[ { "@graph" : [ { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#pubinfo" } ] } ], "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#Head" }, { "@graph" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_1558", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association", "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_1558" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "https://identifiers.org/drugbank:DB14213" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "\"Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. Perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. [see Drug Interactions (7.8) ] [see Warnings and Precautions (5.1) Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema. ( 4 5.1 Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes ( 4 7.8 Do not take a neprilysin inhibitor with perindopril erbumine tablets ( 4 Do not administer perindopril erbumine tablets within 36 hours of switching to or from sacubitril/valsartan ( 4\"" } ], "https://w3id.org/biolink/vocab/provided_by" : [ { "@id" : "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "https://schema.org/MedicalContraindication" } ] }, { "@id" : "https://identifiers.org/drugbank:DB14213", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] } ], "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ] } ], "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q", "http://purl.org/dc/terms/created" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2021-08-25T13:42:34.473+02:00" } ], "http://purl.org/dc/terms/creator" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ { "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ { "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "SQlyhJ8miHaMfcgbRB6fYUABwZ0xjJ0pgQYCZacIZlZeIZIPzRX6dkjktoxJrVPuBCEPuHoxg8Qo4wntZ/lS8TgPnmJ76Z/jFCRwWM+oRL2f49tE4SjZ59xk4cT45kfsnI2pjw50r0TkmMebZJ/kjWSJlSTGUy4gnGr59YDLDH0=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q" } ] } ], "@id" : "http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#pubinfo" } ]